Liposomal nanoparticles containing a peptide along with molecules that disrupt critical cellular processes and lower the apoptotic threshold
Background: Cancer cells exhibit a heightened apoptotic threshold, making them resistant to cell death, especially in multidrug-resistant (MDR) cancers. Mitochondrial fusion and fission processes contribute to this resistance by helping cancer cells maintain energy production and survive under stress. Traditional cancer therapies often fail against MDR cancers because these cells have developed mechanisms to resist multiple therapeutic approaches. The ability of cancer cells to evade apoptosis is a major challenge in cancer treatment, particularly in advanced or recurrent cancers. New therapeutic strategies are needed to overcome these resistance mechanisms and effectively induce cancer cell death.
Technical Overview: Northeastern University researchers developed liposomal nanoparticles (NPs) containing a peptide along with molecules that disrupt critical cellular processes and lower the apoptotic threshold of cancer cells. The nanoparticles are designed to deliver their cargo specifically to cancer cells while minimizing toxicity to healthy cells. The peptide component targets specific cellular pathways involved in apoptosis resistance, while the small molecules work synergistically to disrupt mitochondrial function and other survival mechanisms. The liposomal delivery system ensures efficient uptake by cancer cells and controlled release of the therapeutic agents.
Benefits:
Application:
Opportunity: Seeking licensee/industry partner/funding